[1] Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol, 2019, 70: 531-544. [2] Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol, 2018, 53: 362-376. [3] Su Q, Kumar V, Sud N, et al. MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis. Adv Drug Deliv Rev, 2018, 129: 54-63. [4] Szabo G, Csak T. Role of MicroRNAs in NAFLD/NASH. Dig Dis Sci, 2016, 61: 1314-1324. [5] Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol, 2018, 53: 362-376. [6] Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis. Hepatology, 2019, 70: 1119-1133. [7] He Y, Hwang S, Cai Y, et al. MicroRNA-223 ameliorates nonalcoholic steatohepatitis and cancer by targeting multiple inflammatory and oncogenic genes in hepatocytes. Hepatology, 2019, 70: 1150-1167. [8] Zhang M, Sun W, Zhou M, et al. MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1. Sci Rep, 2017, 7: 14493-14502. [9] Meng Z, Fu X, Chen X, et al. miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology, 2010, 52: 2148-2157. [10] Wu JC, Chen R, Luo X, et al. MicroRNA-194 inactivates hepatic stellate cells and alleviates liver fibrosis by inhibiting AKT2. World J Gastroenterol, 2019, 25: 4468-4480. [11] Ran RZ, Chen J, Cui LJ, et al. miR-194 inhibits liver cancer stem cell expansion by regulating RAC1 pathway. Exp Cell Res, 2019, 378: 66-75. [12] Guo Y, Yu J, Wang C, et al. miR-212-5p suppresses lipid accumulation by targeting FAS and SCD1. J Mol Endocrinol, 2017, 59: 205-217. |